KEIO RESEARCHERS INFORMATION SYSTEM

Career 【 Display / hide 】

Career 【 Display / hide 】

• 2000.05

  -

  2002.04

  慶應義塾大学医学部, 内科学, 研修医

• 2002.05

  -

  2004.05

  慶應義塾大学医学部, 内科学, 専修医

• 2004.06

  -

  2010.01

  慶應義塾大学医学部, 内科学(呼吸器), 助手

• 2007.01

  -

  2010.01

  慶應義塾大学医学部, 微生物学・免疫学, 研究員

• 2008.07

  -

  2010.01

  佐野厚生総合病院, 内科, 医員

display all >>

Academic Background 【 Display / hide 】

Academic Background 【 Display / hide 】

• 2000.03

  Keio University, Faculty of Medicine, 医学科

  University, Graduated

Academic Degrees 【 Display / hide 】

Academic Degrees 【 Display / hide 】

• 博士, Keio University, Dissertation, 2008.06

Licenses and Qualifications 【 Display / hide 】

Licenses and Qualifications 【 Display / hide 】

• 医師免許, 2000.04

Research Areas 【 Display / hide 】

Research Areas 【 Display / hide 】

• Life Science / Respiratory medicine

• Life Science / Infectious disease medicine

Research Keywords 【 Display / hide 】

Research Keywords 【 Display / hide 】

• Mycobacteriosis

Books 【 Display / hide 】

Books 【 Display / hide 】

• EBM呼吸器疾患の治療2016-2017

  Nishimura Tomoyasu, 中外医学社, 2016.01

  Scope: Interferon Gamma Release Assayの有用性は？

• 新 呼吸器専門医テキスト

  Nishimura Tomoyasu, 南江堂, 2015.04

  Scope: 肺結核症

• 内科研修マニュアル　改訂第2版

  Nishimura Tomoyasu, 南江堂, 2006.07

  Scope: 市中肺炎/院内肺炎

Papers 【 Display / hide 】

Papers 【 Display / hide 】

• Inactivation of nontuberculous mycobacteria by gaseous ozone treatment

  Misawa K., Nishimura T., Kashimura S., Hasegawa N.

  Journal of Infection and Chemotherapy （Journal of Infection and Chemotherapy)  29 （ 6 ） 628 - 630 2023.06

  ISSN  1341321X

  　View Summary

  Nontuberculous mycobacteria (NTM) are environmental bacteria resistant to many common disinfectants and ultraviolet radiation. Inhalation of aerosols generated from NTM-containing water and soil causes NTM lung disease, especially in people with underlying lung diseases and decreased immunity. To prevent healthcare-acquired NTM infections, it is important to eradicate NTM living in hospital environments. Therefore, we evaluated the efficacy of gaseous ozone for the inactivation of NTM, namely Mycobacterium (M.) avium, M. intracellulare, M. kansasii, M. abscessus subsp. abscessus and M. abscessus subsp. massiliense. Gaseous ozone treatment at 1 ppm for 3 h reduced the bacterial number of all strains by more than 97%. Gaseous ozone treatment could be a practical, effective and convenient disinfection method for NTM living in hospital environments.

  • Access to Document (DOI)

• Osteoporosis in nontuberculous mycobacterial pulmonary disease: a cross-sectional study

  Tanaka H., Asakura T., Suzuki S., Okamori S., Kusumoto T., Ogawa T., Uno S., Morita A., Lee H., Namkoong H., Kamata H., Sato Y., Uwamino Y., Nishimura T., Ishii M., Fukunaga K., Hasegawa N.

  BMC Pulmonary Medicine （BMC Pulmonary Medicine)  22 （ 1 ）  2022.12

  　View Summary

  Background: Since nontuberculous mycobacterial pulmonary disease (NTM-PD) is common in middle-aged/elderly slender women at risk of osteoporosis, we hypothesized that NTM-PD could be associated with osteoporosis. The study aimed to evaluate the prevalence of osteoporosis in patients with NTM-PD compared with that in the general population and determine the factors associated with osteoporosis in the subjects, including the serum estradiol (E2) and 25-hydroxyvitamin D (25OHD) levels. Methods: We have recruited 228 consecutive adult patients with NTM-PD from a prospective cohort study at the Keio University Hospital, who had no history of osteoporosis or osteoporosis-associated bone fracture but underwent dual-energy X-ray absorptiometry-based bone mineral density (BMD) evaluation from August 2017–September 2019. The E2 and 25OHD levels were measured in 165 patients with available stored serum samples. We performed multivariable logistic regression analyses for osteopenia and osteoporosis. Results: Osteoporosis (T-score ≤ − 2.5) and osteopenia (T-score − 1 to − 2.5) were diagnosed in 35.1% and 36.8% of patients with NTM-PD, respectively. Compared with the general population, the proportion of osteoporosis was significantly higher in 50–59-, 60–69-, and 70–79-year-old women with NTM-PD. Multivariable analysis revealed that older age (adjusted odds ratio [aOR] for 1-year increase = 1.12; 95% confidence interval [CI] = 1.07–1.18), female sex (aOR = 36.3; 95% CI = 7.57–174), lower BMI (aOR for 1 kg/m2 decrease = 1.37; 95% CI = 1.14–1.65), and chronic Pseudomonas aeruginosa (PA) infection (aOR = 6.70; 95% CI = 1.07–41.8) were independently associated with osteoporosis. Additionally, multivariable analysis in 165 patients whose serum E2 and 25OHD levels were measured showed that both low E2 levels (< 10 pg/mL) and lower 25OHD levels were independently associated with osteoporosis. Conclusions: Middle-aged/elderly women with NTM-PD have a higher prevalence of osteoporosis than the general population. BMD screening should be considered in NTM-PD, especially in older females with severe diseases such as chronic PA infection and lower BMI, and low serum E2 and 25OHD levels.

  • Access to Document (DOI)

• The whole blood transcriptional regulation landscape in 465 COVID-19 infected samples from Japan COVID-19 Task Force

  Wang Q.S., Edahiro R., Namkoong H., Hasegawa T., Shirai Y., Sonehara K., Tanaka H., Lee H., Saiki R., Hyugaji T., Shimizu E., Katayama K., Kanai M., Naito T., Sasa N., Yamamoto K., Kato Y., Morita T., Takahashi K., Harada N., Naito T., Hiki M., Matsushita Y., Takagi H., Ichikawa M., Nakamura A., Harada S., Sandhu Y., Kabata H., Masaki K., Kamata H., Ikemura S., Chubachi S., Okamori S., Terai H., Morita A., Asakura T., Sasaki J., Morisaki H., Uwamino Y., Nanki K., Uchida S., Uno S., Nishimura T., Ishiguro T., Isono T., Shibata S., Matsui Y., Hosoda C., Takano K., Nishida T., Kobayashi Y., Takaku Y., Takayanagi N., Ueda S., Tada A., Miyawaki M., Yamamoto M., Yoshida E., Hayashi R., Nagasaka T., Arai S., Kaneko Y., Sasaki K., Tagaya E., Kawana M., Arimura K., Takahashi K., Anzai T., Ito S., Endo A., Uchimura Y., Miyazaki Y., Honda T., Tateishi T., Tohda S., Ichimura N., Sonobe K., Sassa C.T., Nakajima J., Nakano Y., Nakajima Y., Anan R., Arai R., Kurihara Y., Harada Y., Nishio K., Ueda T., Azuma M., Saito R., Sado T., Miyazaki Y., Sato R., Haruta Y., Nagasaki T., Yasui Y., Hasegawa Y., Mutoh Y., Kimura T., Sato T.

  Nature Communications （Nature Communications)  13 （ 1 ）  2022.12

  　View Summary

  Coronavirus disease 2019 (COVID-19) is a recently-emerged infectious disease that has caused millions of deaths, where comprehensive understanding of disease mechanisms is still unestablished. In particular, studies of gene expression dynamics and regulation landscape in COVID-19 infected individuals are limited. Here, we report on a thorough analysis of whole blood RNA-seq data from 465 genotyped samples from the Japan COVID-19 Task Force, including 359 severe and 106 non-severe COVID-19 cases. We discover 1169 putative causal expression quantitative trait loci (eQTLs) including 34 possible colocalizations with biobank fine-mapping results of hematopoietic traits in a Japanese population, 1549 putative causal splice QTLs (sQTLs; e.g. two independent sQTLs at TOR1AIP1), as well as biologically interpretable trans-eQTL examples (e.g., REST and STING1), all fine-mapped at single variant resolution. We perform differential gene expression analysis to elucidate 198 genes with increased expression in severe COVID-19 cases and enriched for innate immune-related functions. Finally, we evaluate the limited but non-zero effect of COVID-19 phenotype on eQTL discovery, and highlight the presence of COVID-19 severity-interaction eQTLs (ieQTLs; e.g., CLEC4C and MYBL2). Our study provides a comprehensive catalog of whole blood regulatory variants in Japanese, as well as a reference for transcriptional landscapes in response to COVID-19 infection.

  • Access to Document (DOI)

• In vitro effects of diazabicyclooctane β-lactamase inhibitors relebactam and nacubactam against three subspecies of Mycobacterium abscessus complex

  Misawa K., Nishimura T., Kashimura S., Enoki Y., Taguchi K., Uno S., Uwamino Y., Matsumoto K., Hasegawa N.

  International Journal of Antimicrobial Agents （International Journal of Antimicrobial Agents)  60 （ 5-6 ）  2022.11

  ISSN  09248579

  　View Summary

  Background: Mycobacterium abscessus complex (MABC) pulmonary disease is notoriously difficult to treat due to intrinsic resistance to many common antibiotics. MABC is β-lactam-resistant as it produces class A β-lactamases, such as blaMab, which are inhibited by diazabicyclooctane (DBO) β-lactamase inhibitors. Objectives: To investigate the microbiological effects of the combination of β-lactam and DBO β-lactamase inhibitors (relebactam and nacubactam) against MABC and determine if the effects are associated with the MABC subspecies and colony morphotype. Methods: The antimicrobial susceptibility of three type strains and 20 clinical isolates of MABC to the combination of seven β-lactams with relebactam or nacubactam was evaluated using broth microdilution checkerboard assays. For these strains, expression levels of blaMab were assessed using quantitative real-time polymerase chain reaction and genotypic diversity was evaluated using 18-locus variable number tandem repeat assay. Results: Relebactam and nacubactam lowered the minimum inhibitory concentrations of β-lactams, particularly imipenem, meropenem, and tebipenem, against MABC. There was no difference in efficacy of combination treatment between three subspecies, but rough morphotypes tended to be less susceptible than smooth morphotypes. There were no differences in blaMab expression levels and genotypic diversity between the morphotypes. Conclusions: The combination of β-lactam with relebactam or nacubactam improved the efficacy of β-lactams against all MABC subspecies, but higher concentrations of β-lactams were needed for rough morphotypes.

  • Access to Document (DOI)

• DOCK2 is involved in the host genetics and biology of severe COVID-19

  Namkoong H., Edahiro R., Takano T., Nishihara H., Shirai Y., Sonehara K., Tanaka H., Azekawa S., Mikami Y., Lee H., Hasegawa T., Okudela K., Okuzaki D., Motooka D., Kanai M., Naito T., Yamamoto K., Wang Q.S., Saiki R., Ishihara R., Matsubara Y., Hamamoto J., Hayashi H., Yoshimura Y., Tachikawa N., Yanagita E., Hyugaji T., Shimizu E., Katayama K., Kato Y., Morita T., Takahashi K., Harada N., Naito T., Hiki M., Matsushita Y., Takagi H., Aoki R., Nakamura A., Harada S., Sasano H., Kabata H., Masaki K., Kamata H., Ikemura S., Chubachi S., Okamori S., Terai H., Morita A., Asakura T., Sasaki J., Morisaki H., Uwamino Y., Nanki K., Uchida S., Uno S., Nishimura T., Ishiguro T., Isono T., Shibata S., Matsui Y., Hosoda C., Takano K., Nishida T., Kobayashi Y., Takaku Y., Takayanagi N., Ueda S., Tada A., Miyawaki M., Yamamoto M., Yoshida E., Hayashi R., Nagasaka T., Arai S., Kaneko Y., Sasaki K., Tagaya E., Kawana M., Arimura K., Takahashi K., Anzai T., Ito S., Endo A., Uchimura Y., Miyazaki Y., Honda T., Tateishi T., Tohda S., Ichimura N., Sonobe K., Sassa C.T., Nakajima J., Nakano Y., Nakajima Y., Anan R., Arai R., Kurihara Y., Harada Y., Nishio K.

  Nature （Nature)  609 （ 7928 ） 754 - 760 2022.09

  ISSN  00280836

  　View Summary

  Identifying the host genetic factors underlying severe COVID-19 is an emerging challenge1–5. Here we conducted a genome-wide association study (GWAS) involving 2,393 cases of COVID-19 in a cohort of Japanese individuals collected during the initial waves of the pandemic, with 3,289 unaffected controls. We identified a variant on chromosome 5 at 5q35 (rs60200309-A), close to the dedicator of cytokinesis 2 gene (DOCK2), which was associated with severe COVID-19 in patients less than 65 years of age. This risk allele was prevalent in East Asian individuals but rare in Europeans, highlighting the value of genome-wide association studies in non-European populations. RNA-sequencing analysis of 473 bulk peripheral blood samples identified decreased expression of DOCK2 associated with the risk allele in these younger patients. DOCK2 expression was suppressed in patients with severe cases of COVID-19. Single-cell RNA-sequencing analysis (n = 61 individuals) identified cell-type-specific downregulation of DOCK2 and a COVID-19-specific decreasing effect of the risk allele on DOCK2 expression in non-classical monocytes. Immunohistochemistry of lung specimens from patients with severe COVID-19 pneumonia showed suppressed DOCK2 expression. Moreover, inhibition of DOCK2 function with CPYPP increased the severity of pneumonia in a Syrian hamster model of SARS-CoV-2 infection, characterized by weight loss, lung oedema, enhanced viral loads, impaired macrophage recruitment and dysregulated type I interferon responses. We conclude that DOCK2 has an important role in the host immune response to SARS-CoV-2 infection and the development of severe COVID-19, and could be further explored as a potential biomarker and/or therapeutic target.

  • Access to Document (DOI)

display all >>

Papers, etc., Registered in KOARA 【 Display / hide 】

Papers, etc., Registered in KOARA 【 Display / hide 】

• Measures against mycobacteriosis at Keio University

  Nishimura, Tomoyasu

  学事振興資金研究成果実績報告書 （慶應義塾大学)  2018

• Elucidation of the host immune response to nontuberculous mycobacterial cell wall lipids

  Nishimura, Tomoyasu

  科学研究費補助金研究成果報告書 2018

• Elucidation of miRNA-mediated pathophysiology of MAC pulmonary disease

  Nishimura, Tomoyasu

  科学研究費補助金研究成果報告書 2018

• Tuberculosis countermeasures for the top global university project in Keio University

  Nishimura, Tomoyasu

  学事振興資金研究成果実績報告書 （慶應義塾大学)  2017

• Association of sex steroid hormones and non-tuberculous mycobacteriosis

  Nishimura, Tomoyasu

  科学研究費補助金研究成果報告書 2017

display all >>

Presentations 【 Display / hide 】

Presentations 【 Display / hide 】

• 外国人留学生を対象とした結核感染調査

  西村知泰，森正明，牧野伸司，広瀬寛，和井内由充子，横山裕一，武田彩乃，畔上達彦，後藤伸子，河邊博史

  第116回日本内科学会総会・講演会 (名古屋) , 

  2019.04

  , 

  Poster presentation

• 肺MAC症の新規検査法

  Nishimura Tomoyasu

  第101回日本細菌学会関東支部総会 (東京) , 

  2018.11

  , 

  Symposium, workshop panel (nominated)

• アスペルギルス沈降抗体陽性である肺Mycobacterium avium complex症患者の臨床的特徴

  鈴木翔二, 朝倉崇徳, 南宮湖, 岡森慧, 八木一馬, 鎌田浩史, 舩津洋平, 中野泰, 西村知泰, 石井誠, 海老原全, 別役智子, 長谷川直樹．

  第58回日本呼吸器学会学術講演会 (大阪) , 

  2018.04

  , 

  Poster presentation

• 大学生における先天性心疾患の管理状況

  牧野伸司, 和井内由充子, 武田彩乃, 畔上達彦, 広瀬寛, 西村知泰, 横山裕一, 河邊博史, 森正明．

  第115回日本内科学会年次学術講演会 (京都) , 

  2018.04

  , 

  Poster presentation

• 当大学医学部留学生に対するImmunization Recordの運用と考察

  武藤志保, 横山裕一, 弦巻美保, 齋藤圭美, 西村知泰, 森正明, 河邊博史．

  第55回全国大学保健管理研究集会 (宜野湾) , 

  2017.11

  , 

  Poster presentation

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide 】

Research Projects of Competitive Funds, etc. 【 Display / hide 】

• 肺MAC症の新規治療法開発に向けた菌細胞壁脂質の解析

  2023.04

  -

  2026.03

  文部科学省・日本学術振興会, 科学研究費補助金, Research grant, Principal investigator

• 肺非結核性抗酸菌症患者の宿主疾患感受遺伝子の機能解析による新規治療基盤の創出

  2023.04

  -

  2026.03

  文部科学省・日本学術振興会, 科学研究費補助金, Research grant, Coinvestigator(s)

• 個細胞空間的degradome解析に基づくプロテアーゼを介したがん免疫制御の解明

  2022.04

  -

  2026.03

  文部科学省・日本学術振興会, 科学研究費補助金, Research grant, Coinvestigator(s)

• 末梢気道病変に着目した肺NTM症の新たな治療標的の創出

  2022.04

  -

  2025.03

  国立研究開発法人日本医療研究開発機構, 新興・再興感染症研究基盤創生事業, Commissioned ｒesearch, Coinvestigator(s)

• ムチン異常集積に着目した肺非結核性抗酸菌症の病態解明

  2021.10

  -

  2024.03

  文部科学省・日本学術振興会, 科学研究費補助金, Research grant, Coinvestigator(s)

display all >>

Courses Taught 【 Display / hide 】

Courses Taught 【 Display / hide 】

• MEDICINE IN MODERN SOCIETY 2

  2023

• INFECTIOUS DISEASES

  2023

• INFECTIOUS DISEASES

  2022

• INFECTIOUS DISEASES

  2021

• INFECTIOUS DISEASES

  2020

display all >>

Courses Previously Taught 【 Display / hide 】

Courses Previously Taught 【 Display / hide 】

• 感染症学

  Keio University

  2018.04

  -

  2019.03

  , 

  Full academic year, Other, Lecture, Lecturer outside of Keio

• 現代社会と医学Ⅱ

  Keio University

  2018.04

  -

  2019.03

  , 

  Full academic year, Other, Lecture, Within own ｆaculty

Social Activities 【 Display / hide 】

Social Activities 【 Display / hide 】

• 平成27年度外務省巡回医師団

  2016.02

  -

  2016.03

• 平成26年度外務省巡回医師団

  2015.01

  -

  2015.02

Memberships in Academic Societies 【 Display / hide 】

Memberships in Academic Societies 【 Display / hide 】

• 日本免疫学会

  　

• 日本内科学会

  　

• 日本呼吸器学会

  　

• 日本呼吸器内視鏡学会

  　

• 日本感染症学会

  　

display all >>

Committee Experiences 【 Display / hide 】

Committee Experiences 【 Display / hide 】

• 2016.04

  -

  Present

  評議員, 日本感染症学会